Press Releases August 31, 2026 04:05 PM

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

Stryker enhances shoulder care portfolio with acquisition of rotator cuff augmentation technology from ZuriMED

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
SYK

Stryker Corporation has signed a definitive agreement to acquire ZuriMED, the developer of the FiberLocker System, a novel rotator cuff augmentation technology designed to improve biomechanical strength and reduce clinical failures in rotator cuff repair. This acquisition bolsters Stryker's shoulder portfolio, supporting specialists in sports medicine and arthroplasty, and reflects the company's commitment to innovation and improved patient outcomes in a rapidly growing segment.

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
SYK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Stryker acquires ZuriMED to add FiberLocker System to its shoulder care offerings, focusing on rotator cuff augmentation.
  • Rotator cuff repair is one of the fastest-growing segments in sports medicine, representing significant market opportunity.
  • The FiberLocker System addresses a critical clinical failure mode, enhancing biomechanical strength and patient outcomes in rotator cuff repair.

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

  • Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.
  • The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.
  • The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.

Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine and represents a significant opportunity within shoulder care.1 The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.

“ZuriMED has developed a differentiated technology that addresses an important clinical need within shoulder care,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio. This acquisition reflects our continued commitment to advancing innovation and improving patient outcomes.”

This transaction is subject to customary closing conditions. Stryker and ZuriMED will continue to operate as separate entities and proceed with business as usual until the transaction closes.

About Stryker        
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead
Vice President, Investor Relations
nick.mead@stryker.com

For media inquiries:
Kim Montagnino
Vice President, Chief Communications Officer
kim.montagnino@stryker.com

References

  1. Mordor Intelligence. Rotator Cuff Treatment Market Size and Share Analysis – Growth, Trends, and Forecasts (2026–2031). Mordor Intelligence report.


Risks

  • Completion of the acquisition is subject to customary closing conditions, which could delay or prevent the deal.
  • Integration of ZuriMED's technology and operations into Stryker may face operational or execution challenges.
  • Market adoption of the FiberLocker System depends on clinical acceptance and reimbursement environments within medical device and healthcare sectors.

More from Press Releases

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company Sep 2, 2026 uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Sep 2, 2026 Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Sep 2, 2026 Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference Sep 2, 2026 Aeluma to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 16, 2026 Sep 2, 2026